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Abstract
TGFBI has been shown to sensitize ovarian cancer cells to the cytotoxic effects of paclitaxel
via an integrin receptor-mediatedmechanism that modulatesmicrotubule stability. Herein,
we determine that TGFBI localizes within organized fibrillar structures in mesothelial-
derived ECM.We determined that suppression of SPARC expression by shRNA decreased
the deposition of TGFBI in mesothelial-derivedECM, without affecting its overall protein
expression or secretion. Conversely, overexpression of SPARC increased TGFBI deposi-
tion. A SPARC-YFP fusion construct expressed by the Met5a cell line co-localized with
TGFBI in the cell-derived ECM. Interestingly, in vitro produced SPARC was capable of pre-
cipitating TGFBI from cell lysates dependent on an intact SPARC carboxy-terminus with in
vitro binding assays verifying a direct interaction. The last 37 amino acids of SPARC were
shown to be required for the TGFBI interaction while expression of a SPARC-YFP construct
lacking this region (aa 1–256) did not interact and co-localize with TGFBI in the ECM. Fur-
thermore, ovarian cancer cells have a reducedmotility and decreased response to the che-
motherapeutic agent paclitaxel when plated on ECM derived frommesothelial cells lacking
SPARC compared to control mesothelial-derived ECM. In conclusion, SPARC regulates
the fibrillar ECM deposition of TGFBI through a novel interaction, subsequently influencing
cancer cell behavior.
Introduction
The extracellularmatrix (ECM) is crucial for maintaining cell homeostasis, initiating proper
development of the organism, and tissue morphogenesis. During tumorigenesis, however, dys-
regulation of the ECM occurs which may have numerous deleterious effects on cancer
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progression as well as therapeutic response. Distinct tumor-host interactions and contact of
the ECMwith its specific paired integrin receptors can influence both therapeutic response [1–
3] and tumor development [4,5]. In particular, tumors arising from ovarian cancer characteris-
tically deposit themselves throughout the peritoneal cavity subsequently attaching to and
invading mesothelial-lined tissue surfaces in an ECM-rich environment. Due to the predomi-
nant late presentation of high-grade serous (HGS) ovarian cancer, the major difficulty to suc-
cessful treatment is the acquisition of drug resistance. In addition, various ECM components,
including collagen VI, TGFBI, and decorin are associated with an ECM signature in ovarian
cancer that has been implicated in poor prognosis and drug resistance [6–9].
We have previously shown that the secreted ECM protein transforming growth factor beta
induced (TGFBI) sensitizes ovarian cancer cells to the mitotic inhibitor paclitaxel by regulating
microtubule stability via integrin-mediated FAK and RhoA activation [1,3]. In addition,
TGFBI has been shown to be dysregulated in a variety of cancers, including its downregulation
in ovarian cancer [1,10]. Functionally, TGFBI has been shown to bind directly to a number of
cell surface integrin receptors, such as αvß3, α3ß1, and α5ß1, through discrete motifs located
in the conservedFasciclin I domains and in the extreme carboxy-terminus [3,10–14]. As
TGFBI interacts with multiple ECM proteins, including fibronectin and collagen, it has been
proposed to act as a scaffold within the ECM coordinating distinct cellular signal transduction
pathways via cell surface receptors [10]. Furthermore,TGFBImay act as a tumor suppressor
gene, since TGFBI knockout mice develop spontaneous tumors and have upregulated cyclin
D1 expression [15]. Recent identification of TGFBI’s role in chemotherapeutic response and its
possible dysregulation during ovarian cancer progression led to our investigation of its organi-
zation within the extracellular compartment.
Secreted protein acidic and rich in cysteine (SPARC) was originally identified as a bone-spe-
cific protein, called osteonectin,which binds to hydroxyapatite and collagen type I [16].
SPARC is a secreted,multi-domain protein, containing an amino-terminal acidic domain that
binds hydroxyapatite and calcium ions, a follistatin-like domain containing multiple cysteine
residues, and a carboxy-terminal extracellular calcium-binding (EC) domain containing two
EF-hand motifs. Crystal structure of the SPARC EC domain indicates that the collagen-binding
site spans multiple amino acid residues within this carboxy-terminal region [17].
Functionally, SPARC has been associated with the regulation of tissue remodelling through
its ability to alter matrix metalloproteinase expression [18] and modulate cell-ECM interac-
tions via domains in both the amino- and carboxy-termini [19]. Initial studies have implicated
a role in cancer progression as a result of its presence in numerous neoplastic tissues [20]. In
ovarian cancer, it was suggested to have tumor suppressing properties due to its downregula-
tion in ovarian tumors and its ability to inhibit cell growth and tumor formation in xenograft
mouse models [21]. Recent data, utilizing an ovarian cancer syngeneic mouse model, suggests
that the presence of host secreted SPARC limits peritoneal dissemination and ascites formation
[22]. In addition, it has been shown that exogenous SPARC can promote apoptosis in ovarian
cancer cells [23]. Moreover, elevated SPARC expression has been shown to occur in the acti-
vated stroma surrounding ovarian tumors [24,25], leading to the suggestion that it may be
modulating the ovarian tumor microenvironment through regulation of matrix metalloprotei-
nases, inflammation, and pro-migratory cytokines [26].
In this study, we have utilized an in vitro derived extracellularmatrix model system to inves-
tigate the SPARC-TGFBI interrelationship. This work demonstrates SPARC as an upstream
regulator of organized TGFBI fibrils in the ECM. Furthermore, our data suggests that the abil-
ity of SPARC to regulate extracellular TGFBI influences both ovarian cancer motility and
response to the chemotherapeutic agent, paclitaxel.
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Materials andMethods
Antibodies and Reagents
SPARC monoclonal antibody (clone AON-5031; 1:200 Immunofluorescencemicroscopy (IF),
1:1000Western blot (WB)) was purchased fromCambridge Bioscience (Cambridge, UK). Alpha-
tubulin (clone B-5-1-2; 1:3000WB), Collagen I (clone COL-I; 1:200 IF), and Collagen IV (clone
COL-94; 1:200 IF) monoclonal antibodies and actin rabbit polyclonal antibody (1:3000WB) were
purchased from Sigma-Aldrich. Purifiedß1 integrin polyclonal antibody (clone Poly6004; 1:1000
WB) and anti-GSTmonoclonal antibody (1:3000WB) were purchased fromBiolegend (Uithoorn,
Netherlands). Fibronectin (1:300 IF) and FAK monoclonal antibodies (1:1000WB) and GFP poly-
clonal antibody (1:2000WB) were purchased from Invitrogen (Paisley, UK). Affinity purified
polyclonal antibody directed against TGFBI was produced by immunizing rabbits with a C-termi-
nal peptide of human TGFBI (aa 498–683) (1:1000WB). All antibody productionwas performed
in collaborationwith Cambridge Research Biochemicals (Cleveland,UK). TGFBI polyclonal anti-
serum (1:150 IF) was a kind gift fromDr. Ching Yuan (University of Minnesota,Minnesota,
USA). Paclitaxel was purchased from Sigma-Aldrich, cat. no. T7402 (Dorset, UK).
Cell culture
The ovarian cancer SKOV3 cell line and the immortalizedMet5a mesothelial cell line (pur-
chased from LGC standards, Middlesex, UK) were maintained in RPMI media supplemented
with 10% (v/v) heat-inactivated FBS, 50 units/ml penicillin, and 50 μg/ml streptomycin. All
other cell lines (PE01, TR175, SKOV3 TR, PEO188, and A2780) were obtained from Cancer
Research UK Cell Services and cultured in appropriate growth media supplemented with
10% FBS, penicillin, and streptomycin. SKOV3 TR cells were maintained in 0.3 μM paclitaxel.
Short tandem repeats genotyping was performed to confirm the identity of the cell lines. All
transfections were performedwith Lipofectamine 2000 (Invitrogen, Inchinnan Business Park,
Paisley, UK) according to the manufacturer’s instructions. Lentivirus expressing non-target
control shRNA and SPARC shRNA were purchased from Sigma-AldrichMission1 Library.
Five shRNA targets were obtained and tested for their ability to suppress protein expression
assessed by Western blot. Two targets were successful and used for subsequent experiments;
#2–5’-CCTGGACAATGACAAGTACAT -3’ and #5–5’-CTGCCACTTCTTTGCCACAAA-3’.
Cells were infected at a MOI of 10 in the presence of 8 μg/ml of polybrene and subsequent sta-
ble pools of cells were selected in 1.25 μg/ml Puromycin.
Vector cloning and Retrovirus production
SPARC cDNA was purchased fromOriGene (Rockville,MD, USA). Full-length SPARC and
SPARC lacking the carboxy-terminal 47 amino acids (aa 1–256) were PCR cloned into the Hin-
dIII and BamHI restriction sites of the pEYFPN1 vector (Invitrogen). For retrovirus produc-
tion, SPARC cDNA was PCR cloned into the pLNCX2 vector (Invitrogen). Phoenix packaging
cells were utilized for production of retrovirus supernatant [27]. Briefly, cells were transfected
by Calcium phosphate methods (Invitrogen) according to the manufacturer’s protocol and 24
hours post-transfection, cells were refed with fresh complete growth media with viral superna-
tant collected three times every 18 hours. Cells were infected two times at subconfluency in the
presence of 5 μg/ml polybrene and stable pools were selected in 500 μg/ml G418.
Western blot
Cell lysates were harvested in RIPA buffer (1% Triton X-100, 10 mM Tris-HCl pH 7.4, 150
mMNaCl, 5 mM EDTA, 10 μg/ml leupeptin, and 1 mMNa3VO4). Lysates were cleared by
SPARC Regulates TGFBI ECMDeposition
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centrifugation at 14,000xg at 4°C. Protein content was quantified by the BioRadDc Protein
Assay (Hertfordshire, UK). Conditionedmedia was harvested from cells incubated in serum-
free media for 24 hours. Following the addition of 2X SDS-sample buffer, samples were boiled
and loaded onto 10% SDS-PAGE gels and transferred to PVDF (Fisher ScientificUK, Leicester-
shire, UK). Cell-derivedECMwas denuded of cells [28] and extracted directly in 2X SDS-sam-
ple buffer, boiled, and put through a 26-gauge needle before loading on SDS-PAGE.
Membranes were blocked with either 5% non-fat drymilk or 3% BSA, probed with the indi-
cated antibodies, and visualized following the addition of HRP conjugated secondary antibod-
ies (Dako UK Ltd., Cambridgeshire, UK) and incubation with enhanced chemiluminescence
(GE Healthcare UK Ltd., Buckinghamshire, UK).
Apoptosis Assays
Cells were treated with varying concentrations of paclitaxel or DMSO vehicle control diluted in
complete growth media. Following incubation at 37°C for 30 hours, both adherent and floating
cells were harvested and washed once in cold PBS. The TACS Annexin-V Apoptosis kit (R&D
systems Europe Ltd.) was used according to manufacturer’s instructions. For each experiment,
10,000 cell events were recorded on a BD FACS Calibur and data were analyzed with FlowJo
8.8.4 flow cytometry analysis software (Tree Star Inc., Ashland, Oregon, USA). Results were
derived as the percentage of early apoptotic events (Annexin-V positive, propidium iodide neg-
ative) compared to total events. Statistical analysis was performedwith GraphPad Prism1
using two-way ANOVA in conjunction with Bonferroni post-hoc test.
In vitro binding assay
For GST-binding assays, full-length SPARC, SPARC N-terminal (aa 18–134) and SPARC C-
terminal (aa 154–303), SPARC aa 154–175, SPARC aa 176–256, SPARC aa 257–303, SPARC
aa 154–256, SPARC aa 176–303, and SPARC aa 18–266 constructs were subcloned into the
pGEX4T2 vector (GE Healthcare). All GST-fusion proteins were prepared and purified from
Rosetta BL21 DE3 E. coli using Glutathione sepharose 4B beads (GE Healthcare). The pET27
TGFBI vector was a kind gift from Dr. Ching Yuan (University of Minnesota,Minnesota,
USA) and recombinant TGFBI was purified from bacteria as previously described [29]. Cells
were lysed in GST lysis buffer (20 mM Tris-HCl pH 7.4, 50 mMNaCl, 1% NP-40, 10% Glyc-
erol, 0.1% ß-mercaptoethanol, and 10 μg/ml Leupeptin). Lysates were centrifuged and the
supernatant was incubated with 10 μg of GST fusion protein and incubated for 2 hours at 4°C
with rotation. For in vitro pull-down assays, 2 μg of rTGFBI or 2 μg human plasma fibronectin
(Merck Millipore) were incubated with 10 μg of GST fusion protein. Glutathione beads were
subsequently washed four times in GST lysis buffer followed by addition of 2X SDS-sample
buffer and boiling.Western blot analysis was performed on samples to probe for precipitated
proteins.
Cell-derivedECM preparation and microscopy
ECM preparation from cells plated on glass coverslips or tissue culture treated dishes was car-
ried out as previously described [28]. Briefly, glass coverslips or tissue culture treated dishes
were pre-coated with 0.2%Gelatin for 1 hour at 37°C, followed by washing with PBS. Following
coating, coverslips and dishes were treated with 1% glutaraldehyde for 30 minutes at room
temperature, washed in PBS, and treated with 1M Ethanolamine for 30 minutes, followed by
washing and storage in PBS. Cells were plated at confluency on gelatin-coated coverslips or
dishes and incubated for 7–10 days in complete growth media with the addition of 50 μg/ml
Ascorbic Acid and refed every 2 days. Cells were either fixed or were denuded from the
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matrices by incubation in PBS containing 0.5% Triton X-100 and 20 mMNH4OH. Matrices
were washed four times in PBS and used for subsequent experiments.
For immunofluorescencemicroscopy, matrices were fixed in 3.7% Formaldehyde in PBS for
8 minutes. Permeabilization with 0.2% Triton X-100 in TBS was performed on intact cells
when appropriate. Matrices or cells were incubated with primary antibody in TBS containing
1% BSA at 37°C for 1.5 hours, washed in TBS, incubated with either Alexa Fluor1 488 or 568
secondary antibodies (Invitrogen) in TBS containing 1% BSA, washed in TBS, and mounted in
Fluorsave (Calbiochem). Images were captured on a Leica Tandem SP5 confocal microscope
(Leica-Microsystems,Milton Keynes, UK) and processed with Adobe Photoshop1 CS2. For
quantitation of TGFBI matrix deposition, the number of enriched TGFBI immunostained foci
were counted for each group from a 10X field of view and this was done for>10 fields of view
and from at least 3 independent experiments. The individual data points were plotted as a
box and whisker blot and represented as number of TGFBI foci/10X field of view. All statistical
analysis was performed in GraphPad Prism1 using one- or two-way Anova in conjunction
with Bonferroni post hoc test. Quantitation of colocalisationwas performed using the JACoP
plugin in ImageJ and a Pearson’s coefficientwas calculated between the red and green
channels.
Time lapse epifluorescence videomicroscopy was performed using a Nikon TE2000 PFS
microscope equipped with a DS-Fi1 CCD camera. SKOV3 cells stably expressing GFP were
replated on Met5A-ECM derived from control shRNA or SPARC shRNA cells on ibidi 35
mm μ-dish, low (Thistle Scientific,Glasgow, UK) and images were taken using a 10X objective
every 2 minutes for 15 hours using NIS elements software (Nikon Instruments Europe) in a
temperature controlled and 5% CO2 maintained environment. Multiple fields were imaged
during each experiment and at least 2 independent experiments were performed. Cell centroid
tracking and analysis of motility was performed over a 10-hour period using Volocity software
(PerkinElmer). All statistical analysis was performed in GraphPad Prism1 using an unpaired
two-tailed t-test.
Results
TGFBI produced by mesothelial cells forms a fibrillarmatrix distinct from
fibronectin
Ovarian cancer dissemination is enhanced by attachment within and along the peritoneal cav-
ity, primarily lined by mesothelial cells. These cells reside in an ECM-rich environment and
due to their influence on carcinogenesis [30,31], may also influence chemotherapeutic
response. In addition, independently, both SPARC and TGFBI have been shown to be associ-
ated with chemotherapeutic drug resistance [1,8,32]. Moreover, the contribution of tumor-
and host-derived ECM components to both ovarian cancer progression and therapeutic
response remains difficult to resolve. Therefore, we assessed the relative protein expression of
TGFBI and SPARC and found that both were expressed at variable levels in a panel of ovarian
cancer cell lines and in the normal, immortalizedMet5A mesothelial cell line both before and
after transforming growth factor beta1 (TGFß1) treatment (Fig 1A).
In order to better understand the role of TGFBI in the ECM and how its organization may
be regulated, we utilized the human immortalizedMet5A mesothelial cell line to evaluate its
ECM localization. TGFBI is arranged into a fibrillarmatrix following a 9-day culture of the
Met5A mesothelial cell line (Fig 1B). The cells can then be denuded from the matrix to allow
better visualization of the ECM and to eliminate immunostaining derived from the cytoplasm
(Fig 1B). Interestingly, the TGFBI fibrillarmatrix is distinct from the fibrillar fibronectin
matrix, indicated by very limited co-localization (Fig 1B). Alternatively, collagen type I in the
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Fig 1. TGFBI produced by mesothelial cells forms a fibrillarmatrix distinct from fibronectin and loss of SPARC expression
disrupts TGFBI deposition inmesothelial-derivedECM. (a)Western blot analysis of RIPA soluble lysates derived from a panel of
ovarian cancer cell lines and theMet5amesothelial cell line either untreatedor treatedwith TGFß1. Themembrane was probedwith
SPARC Regulates TGFBI ECMDeposition
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mesothelial-derivedECM partially co-localizeswith TGFBI (Fig 1B) and abundant amounts of
collagen type IV are deposited and organized into fibrillar structures in the mesothelial-derived
ECM and also partially co-localizeswith TGFBI (Fig 1B), consistent with reports suggesting a
functional interaction betweenTGFBI and some collagen isoforms [33].
Loss of SPARC expression disrupts TGFBI deposition in mesothelial-
derived ECM
Previous literature has suggested that SPARC may function in the ECM as a scaffold, modulating
the organization of various ECM components, such as fibronectin and collagen [34,35]. There-
fore, we next assessedwhether SPARC was necessary for TGFBI organization in the ECM.
Although ovarian cancer cells such as PEO1 express and secrete both TGFBI and SPARC (Fig
1A), while SKOV3 primarily only express TGFBI, their extracellularmatrix is not well organized
and the TGFBI fibrillar deposition is almost non-existent (S1A Fig). We therefore utilized the
Met5A cell line since it produces a well-organized ECMwith abundant amounts of deposited
fibrillar TGFBI (Fig 1A and 1B) to evaluate the SPARC-TGFBI relationship. Stable suppression
of SPARC protein expression in theMet5A cell line was achieved by introduction of two separate
shRNA targets against SPARC by Lentivirus infection. Following successful suppression of
SPARC expression, as assessed byWestern blot and immunofluorescencemicroscopy (Fig 1C;
S1B and S1C Fig), we utilized these cells to evaluate the organization of the ECM. Following cul-
ture of the stable-expressing SPARC shRNA cells for a period of 9 days, cells were denuded from
the depositedmatrix and the ECMwas analyzed for TGFBI expression by immunofluorescence
microscopy. Interestingly, in cells lacking SPARC protein expression, there was a significant
decrease in TGFBI immunostaining in the mesothelial-derivedmatrices, although the fibronectin
matrix remained unchanged (Fig 1D). Visualized at lower magnification, the patchy organization
of TGFBI in the ECM is characterized by enriched foci of TGFBI fibrillar immunoreactivity.
When quantified, the SPARC shRNA expressing cells show a significant reduction in TGFBI
enriched foci within the mesothelial-derivedECM (Fig 1E). In contrast, the Collagen type IV
matrix remained unchanged in cells stably expressing SPARC shRNA compared to non-target
control shRNA (S1D Fig). Importantly, the loss of TGFBI immunoreactivity was not due to a
decrease in overall protein expression (Fig 1C) or a decrease in secretion of TGFBI into the
media (Fig 1F). Therefore, stable suppression of SPARC protein expression leads to a decrease in
fibrillar TGFBI depositionwithinmesothelial-derivedECM.
Modulation of SPARC expression influences TGFBI deposition in
mesothelial-derived ECM
Our data indicates that loss of SPARC subsequently leads to a decrease in TGFBI immunos-
taining in mesothelial-derivedECM.We further evaluated this phenotype in the context of
antibodies specific to the indicated proteins. (b) Confocal microscopy of Met5a cells and extracellular matrix preparationsdenuded of
Met5a cells cultured for 9 days, was performed following immunostaining for TGFBI, fibronectin, Collagen type I, and Collagen type IV.
Hoechst dye was utilized to visualize nuclei andmerged images are indicated. Scale bar 40 μm.Quantitation of colocalisation from >3
fields of view were performedand represented as a Pearson’s coefficient. Error bars indicate s.d., ****p<0.0001, ***p<0.001. (c) RIPA
soluble lysates harvested fromMet5a cells stably expressing either control non-target shRNA or SPARC shRNA target #2 and #5, while
cultured under 3Dmatrix conditions. Western blot analysis was performedutilizing antibodies specific to the indicated proteins. (d)
Confocal microscopy of matrix preparations fromMet5a cells stably expressing non-target shRNA, SPARC shRNA #2, or SPARC shRNA
#5 immunostained for TGFBI and fibronectin. Merged images are indicated. Arrows indicate individual foci. Scale bar 200 μm. (e)
Quantitation of results from immunostainedmatrices. The number of enrichedTGFBI immunostained foci were counted from each group
and represented as number of TGFBI foci/10X field of view. ***represents significance from control of p<0.001, ANOVA. (f) Conditioned
media was harvested fromMet5a cells stably expressing either control non-target shRNA or SPARC shRNA #5, while cultured under 3D
matrix conditions. Western blot was performedutilizing antibodies specific to the indicated proteins.
doi:10.1371/journal.pone.0162698.g001
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overexpression of SPARC in mesothelial cells. Following infectionwith retrovirus expressing
SPARC cDNA and the generation of stable expressing pools of Met5A cells, overexpression of
SPARC protein was validated by Western blot and immunofluorescencemicroscopy with a
comparison to non-target (wild-type) and SPARC shRNA expressing cells (Fig 2A; S1B and
S1C Fig). In contrast to a study performed in a glioblastoma cell line [36], overall expression
and secretion of TGFBI was unaffected by either loss or gain of SPARC in the Met5a cell line
(Figs 1F and 2B). Interestingly, following the 9 day culture and the production of mesothelial-
derived ECM, SPARC overexpression increased TGFBI deposition in mesothelial-derived
ECM, verified by quantitation of enriched TGFBI immunoreactive foci (Fig 2C and 2D). How-
ever, this impact on ECM deposition was not due to an overall change in Met5a cellular mor-
phology, as paxillin-immunopositive focal adhesions remain unchanged and there was a lack
of E-cadherin-mediated cell-cell junctions under all conditions (S2A Fig). Furthermore,
extraction of the mesothelial-derivedECM from SPARC shRNA and SPARC-overexpressing
cells followed by Western blot analysis verified the respective loss and gain of TGFBI deposi-
tion in the ECM fraction (Fig 2E). In conclusion, the level of SPARC protein expression regu-
lates TGFBI deposition in mesothelial-derivedECM, but not the intracellular or secreted
amounts of TGFBI.
SPARC co-localizes with TGFBI in mesothelial-derived ECM
Our data indicates SPARC is a necessary component to organize fibrillar TGFBI in the ECM.
We next determinedwhether SPARC and TGFBI co-localize in the mesothelial-derivedECM.
Since antibodies against the endogenous SPARC protein revealed only weak immunostaining
of SPARC (data not shown), we utilized a SPARC-YFP fusion protein to evaluate its localiza-
tion following expression in Met5a cells (Fig 3A and 3B). Met5a cells were transiently trans-
fected with SPARC-YFP and cultured for a period of 6 days prior to immunostaining of the
cell-denuded ECM. SPARC-YFP was able to organize into an insoluble matrix characterized by
punctate or fibrillar structures that was colocalizedwith TGFBI (Fig 3B). By contrast, SPAR-
C-YFP showed minimal colocalizationwith fibronectin (Fig 3B).
SPARC directly interacts with TGFBI via its carboxy-terminus
Similar to TGFBI, SPARC has been reported to bind multiple ECM proteins, including differ-
ent collagen isoforms, thrombospondin, and vitronectin [37,38]. Since TGFBI and SPARC
have similar binding partners and co-localize in the ECM, we assessed whether TGFBI
directly interacts with SPARC. First, we utilized GST-SPARC fusion proteins in pull-down
assays from SKOV3 cell lysates. GST-SPARC was capable of precipitating TGFBI as well as
alpha-tubulin, which was previously characterized as a SPARC binding partner [39]. The
negative control, actin, was unable to bind SPARC (Fig 4A). As SPARC interacts with colla-
gens via its carboxy-terminal EC domain [19,40], we determined the region of SPARC spe-
cific for its interaction with TGFBI using truncated GST-SPARC constructs and SKOV3
lysates. The carboxy-terminus of SPARC, comprising amino acids 154–303, was necessary
for binding to TGFBI (Fig 4B).
To determine whether the interaction between TGFBI and SPARC was direct, we utilized
purified recombinant TGFBI (rTGFBI) and a GST-SPARC fusion protein. Incubation of
rTGFBI and GST-SPARC proteins followed by precipitation of GST-SPARC using Glutathione
sepharose beads confirmed a direct interaction between the two proteins, dependent on an
intact carboxy-terminus of SPARC (Fig 4C). Similar to work by others, SPARC was unable to
interact with purified fibronectin (Fig 4C)[37].
SPARC Regulates TGFBI ECMDeposition
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Interaction of SPARC with TGFBI is necessary for TGFBI extracellular
matrix deposition
We next asked whether the TGFBI binding site on SPARC was necessary for co-localization
and regulation of TGFBI deposition in the ECM. To further dissect the function of the SPARC
carboxy-terminus, we performedGST pull-down assays from SKOV3 lysates with different
Fig 2. Modulation of SPARC expression influencesTGFBI deposition inmesothelial-derivedECM.
RIPA soluble lysates (a) and conditioned media (b) were harvested fromMet5a cells stably expressing either
control non-target shRNA, overexpressing SPARC cDNA, or SPARC shRNA #5, while cultured under 3D
matrix conditions. Western blot analysis was performedusing antibodies specific to the indicated proteins. (c)
Confocal microscopy was performedon ECMpreparations fromMet5a cells stably expressing non-target
shRNA, SPARC shRNA #5, or overexpressing SPARC cDNA immunostained for TGFBI and fibronectin as
indicated. Merged images are indicated. Arrows indicate individual foci. Scale bar 200 μm. (d) Level of TGFBI
immunostaining was quantified by counting TGFBI enriched immunostained foci from each group and
represented by number of TGFBI foci/10X field of view. ***represents significance from control of p<0.001,
ANOVA. (e) Matrix denuded of Met5a cells was solubilised in SDS-sample buffer andWestern blot analysis
was performed utilizing antibodies to the indicated proteins.
doi:10.1371/journal.pone.0162698.g002
Fig 3. SPARC colocalizes with TGFBI inmesothelial-derivedECM. (a)Western blot analysis was performed on RIPA soluble lysates
harvested fromMet5a cells transfected with either YFP alone or SPARC-YFP. Immunoblotting with anti-GFPantibody recognizes YFP fusion
constructs. (b) Extracellular matrix preparationwas carried out fromMet5a cells transfected with SPARC-YFP. Confocal microscopy was
performed following immunostaining for YFP, TGFBI, fibronectin, and SPARC as indicated. Merged images are indicated. Scale bar 40 μm.
doi:10.1371/journal.pone.0162698.g003
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truncated constructs derived from amino acids 154–303. The extreme C-terminus of SPARC
comprising amino acid residues 257–303 was necessary to support maximum binding to
TGFBI (Fig 5A). By contrast, alpha-tubulin predominantly bound to SPARC via a region,
encompassing amino acid residues 154–256, that did not support an interaction with TGFBI
(Fig 5A). Furthermore, a GST fusion protein encompassing full-length SPARC lacking the last
37 amino acids (a.a. 18–266) was unable to bind TGFBI, but still capable of binding alpha-
tubulin (Fig 5B). Therefore, a region of 37 amino acids in the extreme carboxy-terminus of
SPARC is necessary for its interaction with TGFBI.
We next immunostained ECMderived fromMet5a cells expressing a SPARC-YFP construct
encompassing amino acid residues 1–256 and therefore lacking the TGFBI binding site (Fig
5C). Although there was limited deposition of this construct in the ECM, there was a clear lack
of TGFBI expression and co-localization compared to control cells expressing full-length
SPARC-YFP (Fig 5D and 5E). The impaired organization of SPARC-YFP a.a. 1–256 in the
ECMmay be due to partial loss of the Collagen-binding site, which has been shown to be nec-
essary to sequester SPARC in the ECM [41]. In addition, a truncated SPARC-YFP fusion pro-
tein containing amino acid residues 18–134 and therefore lacking both the Collagen and
TGFBI binding site (Fig 4) [17], was incapable of being deposited and organized into fibrillar
structures in the mesothelial-derivedECM, and did not co-localizewith TGFBI (data not
shown). In conclusion, SPARC and TGFBI interact biochemically, and this interaction is neces-
sary for TGFBI deposition and their co-localization in the ECM.
Mesothelial-derived ECM influences cancer cell motility and response to
the chemotherapeutic agent paclitaxel
Our previous work has identified expression of TGFBI to be necessary for sensitizing ovarian
cancer cells to paclitaxel-induced cell death [1]. Since SPARC regulates TGFBI deposition in
the ECM, we determined how the Met5A-derived ECM could influence cancer cell motility
and response to paclitaxel. First, we evaluated the motility of SKOV3 cells plated on different
Met5A-derived ECMs. SKOV3 cells that stably expressed GFP were tracked, using centroid
measurements, on ECM derived fromMet5A cells expressing either control or SPARC shRNA.
A significant decrease in tracking distance and tracking velocity was observed for SKOV3 cells
plated on ECM lacking SPARC (- SPARC) compared to control matrices (Fig 6A; S2B, S3 and
S4 Figs), while there was no change in the mode of migration as measured by the meandering
index (data not shown).
We next evaluated the paclitaxel response of SKOV3 cells following plating on either plastic,
control Met5A derived ECM, or Met5A SPARC shRNA derived ECM (- SPARC). Met5A-
derived ECM increased the sensitivity of SKOV3 cells to paclitaxel-induced death as compared
to plastic, whereas on ECM derived from SPARC shRNA cells, which lacks TGFBI, a signifi-
cantly lower response to paclitaxel was observed at concentrations of 0.03μM and 0.3μM
(Fig 6B).
Fig 4. SPARC directly interactswith TGFBI via its carboxy-terminus. (a) In vitroGST-binding assays.
Coomassie stained gel of purifiedGST and GST-SPAR C (aa 18–303) expressed in bacteria.Western blot analysis
was performed following GST pull-down fromSKOV3 lysates, probedwith antibodies specific to the indicated
proteins. (b) Coomassie stained gel of bacterially expressed and purifiedGST, GST-SPAR C (aa 18–303),
GST-SPAR C Nterm (aa 18–134), and GST-SPAR CCterm (aa 154–303) fusion proteins.Western blot analysis was
performed following GST pull-down assay fromSKOV3 lysates, probedwith antibodies specific to the indicated
proteins. (c) In vitro binding of purifiedGST-SPAR C to bacterially expressed and purified recombinant TGFBI.GST,
GST-SPAR C (aa 18–303), or GST-SPAR CNterm (aa 18–134) fusion proteinswere incubated with rTGFBI or
fibronectin, followed by pull-downwith Glutathione sepharose 4B beads. Subsequently, Western blot analysis was
performedwith antibodies specific to the indicated proteins. Coomassie stained gel represents experimental input.
doi:10.1371/journal.pone.0162698.g004
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Discussion
In this study, we have defined SPARC as an upstream regulator of TGFBI deposition in the
ECM. This is likely mediated by a novel interaction between TGFBI and SPARC, which occurs
predominantly via the extreme carboxy-terminus of SPARC. Previously, SPARC has been
shown to interact with collagen type I and is necessary for collagen fibrillogenesis in dermal
fibroblasts [16,42]. Additionally, tumors derived from SPARC null mice have a more disorga-
nized and less mature collagenmatrix [43]. Furthermore, during Drosophila development
SPARC is required for Collagen IV and laminin deposition in the basal laminae [44]. Our
results suggest that, in a similar manner, SPARC directly interacts with and organizes TGFBI
into a mature, fibrillar form within the ECM.
Previous work has suggested that SPARC regulates fibronectin organization through a
direct interaction with the intracellular protein integrin-linked kinase (ILK) at the cell-ECM
interface [34]. SPARC was also shown to regulate apoptosis through a direct intracellular inter-
action with caspase 8 [45]. Both these data suggest SPARC may be internalized from the extra-
cellular environment in order to elicit an intracellular role [24,45], thus functioning via inside-
out signalling to modulate both apoptosis and ECM organization. This is supported by data
from ovarian tumor samples illustrating cancer cells lack SPARC mRNA, but do contain
SPARC protein as assessed by immunohistochemistry [24]. Although our data does not sup-
port an intracellular role for SPARC with respect to modulating TGFBI deposition in the ECM,
published literature suggests both a proactive intracellular and extracellular role for SPARC
[24,34,35,45].
It has been suggested that SPARC may influence both tumor stroma formation, through
induction of ECM expression and promote cell migration [35,46], giving further support to
our findings. In addition, elevated SPARC levels correlate with increased invasiveness of ovar-
ian cancers and poor prognosis [47,48]. Along with this, previous reports have associated
SPARC expression with chemotherapy response [8,32,49]. Interestingly, it was suggested that
while loss of endogenous SPARC in a mouse model of ovarian cancer increased tumor growth,
it also increased the response to cisplatin chemotherapy [49]. This is supportive of data from
Jazaeri et al., which indicates elevated SPARC expression in ovarian cancers that were still pres-
ent following platinum-based chemotherapy [8], suggesting a role in therapeutic resistance.
Recent evidence indicates that TGFBI influences ovarian cancer response to paclitaxel by
stabilizing the microtubule cytoskeleton through an integrin-dependent signalling pathway [1].
Since SPARC is secreted into the extracellular tumor microenvironment and is required for
TGFBI fibrillar deposition, its expression may indirectly influence chemotherapeutic response.
Interestingly, both normal and cancer cells elicit growth inhibition when exposed to extracellu-
lar-derived SPARC, but only cancer cells undergo increased apoptosis [23]. Our data illustrates
that the organizedmesothelial-derivedECM has the ability to sensitize ovarian cancer cells to
paclitaxel-induced death. Moreover, loss of SPARC in mesothelial cell-derived ECM has a
Fig 5. Interaction of SPARC with TGFBI is necessary for TGFBI extracellular matrix deposition. (a) GST pull-
down assay fromSKOV3 cell lysates utilizing truncatedGST-fusion proteins derived from the Carboxy-terminus of
SPARC. Following GST-pull down, Western blot analysis was performedutilizing antibodies specific to the indicated
proteins. (b) GST pull-down assay fromSKOV3 cell lysates using either full-length SPARC or full-length SPARC
lacking the carboxy-terminal 37 amino acids (aa 18–266). Following GST-pull-down (PD),Western blot analysis was
performed to the indicated proteins. Coomassie brilliant blue staining of SDS-PAGE confirmsexpression and
purificationof GST fusion proteins. (c) Full-length SPARC-YFP or SPARC-YFP lacking the carboxy-terminal 47
amino acids (SPARC-YFP aa 1–256) were transiently transfected into Met5a cells andWestern blot analysis was
performed to confirm their expression. (d) and (e) Extracellular matrix preparation derived from these cells following
6-day culture was subsequently processed for confocal immunofluorescencemicroscopy. Cell derived ECMwas
immunostained for YFP, TGFBI, and SPARC as indicated. Merged images are indicated. Scale bar 40 μm.
doi:10.1371/journal.pone.0162698.g005
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negative impact on paclitaxel-induced cancer cell death. This is in agreement with previous
data evaluating the response of different cancer cell lines to taxol following plating on 3D-fibro-
blast derived ECM, which indicated there were a subset of cell lines that showed increased sen-
sitivity compared to 2D culture conditions [50].
In addition, SPARC’s ability to remodel the extracellularmatrix suggests it may play a role
in the desmoplastic response, another potential factor influencing chemotherapeutic drug
delivery and treatment response [6,35]. Thus, SPARC may have a dual role in influencing che-
motherapeutic response, first, by organizing the deposition of various ECM components, thus
contributing to a physical barrier to drug delivery and, second, by coordinating cellular signal
transduction events through its ability to act as a molecular scaffold. This is again supported by
recent evidence illustrating that in SPARC null mice ovarian tumors are more responsive to
cisplatin therapy [49]. In addition, it has been suggested that SPARC secreted by macrophages
increases cancer cell migration and metastasis in an integrin-dependentmanner [5], consistent
with our own results (Fig 6A), thus SPARC may also influence cancer dissemination in a
TGFBI-dependentmanner. This is supported by the work of others which suggests a correla-
tion of SPARC and TGFBI expression with tumor metastasis [51]. Moreover, SPARC expres-
sion was previously shown to be elevated in approximately 5% of malignant epithelial cells
within breast tumors and a prognostic indicator of poor outcome [52].
Our data suggests that the TGFBI binding site within the carboxy-terminus of SPARC is a
relatively narrow region in comparison to the binding site for collagen, which spans multiple
amino acid residues in the 5’ end of the EC domain as well as residues in the area between the
two EF hands [17]. A previous report has indicated that Collagen I is necessary for retaining
SPARC, as an insoluble form, in the extracellularmatrix via a direct interaction [41]. Our own
results do not suggest any differences in the Collagen I or the Collagen IV matrix derived from
the Met5a mesothelial cell line in response to modulation of SPARC expression (S1D Fig and
data not shown). However, since SPARC interacts with multiple ECM proteins [37,38], this
does not rule out the possibility that modulation of SPARC expression affects other ECM
components.
In conclusion, our data highlights a novel interaction between two ECM proteins, SPARC
and TGFBI, both previously implicated in modulating chemotherapeutic response, whereby
SPARC regulates TGFBI ECM deposition. Thus, SPARC may modulate the organization of
multiple ECM components, subsequently influencing desmoplasia and drug efficacy in ovarian
cancer. One caveat to consider is that since SPARC may alter both the tumor microenviron-
ment and treatment response, therapies targeted to modulate SPARC functionmay affect both
delivery and response to chemotherapy. In addition, the absence of SPARC may promote
tumor dissemination, as was illustrated in a mouse ovarian cancer model [22], although our
results would suggest this may not be due to an effect on cell migration. Regardless, SPARC is
likely a key component in organizing ECM proteins such as TGFBI in the tumor microenvi-
ronment and both may be prognostic indicators of chemotherapeutic response.
Fig 6. Mesothelial-derived ECM influencescancer cell motility and response to the chemotherapeutic agent
paclitaxel. (a) Time lapse videomicroscopy was performedof SKOV3 cells plated onMet5A derived ECMderived from
cells expressing either control shRNA (Met5Amatrix) or SPARC shRNA (Met5Amatrix—SPARC). Imageswere collected
for 10 hours and cell centroidswere tracked using Volocity software. Circles represent tracking distance and velocity of each
individual cell and black bars represent themean ±S.E.M. (b) SKOV3 cells were plated on either plastic or Met5A derived
ECMderived from cells expressing either control shRNA or SPARC shRNA (- SPARC). Cells were treatedwith 0.003 μM,
0.03 μM, or 0.3 μMpaclitaxel for 30 hours prior to stainingwith FITC-Annexin V and propidium iodide before analyzing by
flow cytometry. Three independent experiments were performed and the results are represented by percent of cells in early
apoptosis (Annexin V +, PI -). ** represents significance of p<0.01 and *** represents significance of p<0.001.
doi:10.1371/journal.pone.0162698.g006
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Supporting Information
S1 Fig. SKOV3 and PEO1 cells have a disorganizedECM, while loss of SPARC has no effect
on Met5A derivedCollagen IV matrix organization. (a) Confocalmicroscopy of ECM
derived from SKOV3 and PEO1 cultured for 9 days prior to ECM extraction. ECMwas immu-
nostained for TGFBI and fibronectin as indicated. Scale bar 40 μm. (b) and (c) Confocal
microscopy of Met5A cells stably expressing either control non-target shRNA, overexpressing
SPARC cDNA, or expressing SPARC shRNA following immunostaining for TGFBI and
SPARC. Nuclei are visualizedwith Hoechst stain and merged images are shown. (d) Met5A
cells stably expressing either non-target control shRNA or SPARC shRNA were cultured for a
period of 9 days prior to cells being denuded from the deposited ECM. Confocalmicroscopy
was performed following immunostaining for TGFBI and Collagen IV. Scale bar = 40 μm.
(TIF)
S2 Fig. Modulation of SPARC expression has no effect on E-cadherin intracellular localisa-
tion or focal adhesion organisation, while SKOV3 cells have decreasedmigration on ECM
derived from SPARC depletedMet5A cells. (a) Confocalmicroscopy of Met5A cells either
stably expressing control non-target shRNA, overexpressing SPARC cDNA, or expressing
SPARC shRNA following immunostaining for TGFBI, E-cadherin, and paxillin. Nuclei are
visualizedwith Hoechst stain and merged images are indicated. Scale bar = 40 μm. (b) Migra-
tion tracks of SKOV3 cells on either Met5A-ECM derived from control shRNA cells or SPARC
shRNA cells following time lapse epifluorescent microscopy. Images were collected every 2
minutes for 10 hours and processed with Volocity software.
(TIF)
S3 Fig. SKOV3 cells plated on Met5A-derived ECM from control shRNA treated cells.
SKOV3 cells are stably expressing GFP and plated on ECM derived from control shRNA
treated Met5A cells. Images captured every 2 minutes. Time display indicates hours:minutes.
(AVI)
S4 Fig. SKOV3 cells plated on Met5A-derived ECM from SPARC shRNA treated cells.
SKOV3 cells are stably expressing GFP and plated on ECM derived from SPARC shRNA
treated Met5A cells. Images captured every 2 minutes. Time display indicates hours:minutes.
(AVI)
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